Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disease-modifying effect after discontinuation of long-term tildrakizumab in moderate-to-severe plaque psoriasis
2019-003218-15Phase 4Terminated
- Sponsor
- Almirall
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of tildrakizumab in plaque psoriasis (2 arms), sponsored by Almirall. Primary endpoint: Blood and skin inflammatory biomarkers presence. Started Sep 2019; status: terminated.
02
Drugs
tildrakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2019-003218-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003218-15.